BioMarin Pharmaceutical (BMRN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$66.53+0.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BMRN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks BMRN against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete integration of Amicus acquisition and drive revenue growth and profitability for GALAFOLD and POMBILITI + OPFOLDA through mid-2030s.
Stated as a priority in 3 of last 3 quarters. Total revenues grew from $766M in 2026-Q1 to $990M in 2026-Q2, driven by the addition of GALAFOLD and POMBILITI + OPFOLDA from the Amicus acquisition. Metabolic Conditions revenue grew 25% year-over-year in 2026-Q2. GAAP net income declined due to acquisition-related costs. Management is delivering revenue growth but integration costs have impacted profitability in the near term.
“Rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA.”
“Addition of GALAFOLD and POMBILITI + OPFOLDA to our commercial portfolio allows us to reach patients and accelerate growth.”
“Announced acquisition of Amicus Therapeutics, including GALAFOLD and POMBILITI + OPFOLDA; expected to accelerate and diversify revenues.”
Drive revenue growth through expanded patient demand and new indications for VOXZOGO and sustained growth in enzyme therapies.
Stated as a priority in 3 of last 3 quarters. VOXZOGO revenue increased from $220M in 2026-Q1 to $253M in 2026-Q2, with full-year 2026 guidance raised to at least $1 billion. VOXZOGO grew 26% year-over-year in 2025. Enzyme Therapies revenue grew 6% year-over-year in 2026-Q1. Management is delivering consistent revenue growth in these key products.
Manage capital allocation prudently, including financing acquisitions and targeting gross leverage below 2.5x by mid-2027.
Stated as a priority in 2 of last 3 quarters. BioMarin secured $3.7 billion of debt financing in 2026-Q1 to support the Amicus acquisition. Long-term debt increased from $597M at 2025 year-end to $1.43B at 2026-Q1. Management targets gross leverage below 2.5x by mid-2027, accelerated by about one year, supported by profitability growth. The trajectory shows active capital allocation and debt management.
Acquire Alesta Therapeutics to add ALE1, a potential first oral therapy for hypophosphatasia, expanding clinical pipeline and rare disease market reach.
Newly stated in 2026-Q3 period. BioMarin announced acquisition of Alesta Therapeutics to add ALE1, a potential first oral therapy for hypophosphatasia, expanding its clinical pipeline and rare disease market presence. The transaction is expected to close in Q3 2026 with modestly dilutive impact on 2026 financials. This is a new strategic growth initiative.
Settle patent disputes with Ascendis Pharma, securing royalty payments on Yuviwel sales in multiple regions through 2030.
Newly stated in 2026-Q3 period. BioMarin entered a global settlement with Ascendis Pharma resolving all pending patent litigation and securing royalty payments of 20% in the U.S. and 18% in EU, Brazil, and South Korea on Yuviwel sales through May 2030. This resolves legal uncertainties and establishes a new royalty revenue stream.
Over the trailing year it converted 1.17x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.
“Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026.”
“The number of children being treated with VOXZOGO increased by more than 20% year-over-year in the first quarter.”
“VOXZOGO generated 26% year-over-year revenue growth for full-year 2025, driven by deeper market penetration.”
“Targeting gross leverage below 2.5 times by mid-year 2027, an acceleration by approximately one year.”
“Secured financing of approximately $3.7 billion of non-convertible debt to support the Amicus acquisition.”